FindTrial
Sign In

The effect of famotidine on reducing the side effects of prostate cancer radiotherapy

Investigating the effectiveness of famotidine as a radioprotector in reducing the mucosal and hematological complications of prostate cancer radiotherapy

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20231121060132N1
Enrollment
50
Registered
2024-01-16
Start date
2023-11-26
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer. Malignant neoplasm of prostate

Interventions

Intervention 1: The control group does not receive any drug. Intervention 2: Intervention group: Famotidine tablets, 40 mg, daily, 4 hours and 3 hours before radiation therapy.

Sponsors

Kermanshah University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
30 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients aged 30 to 75 with prostate cancer candidates for radiotherapy Do not receive PPI drugs and other H2 antagonist drugs

Exclusion criteria

Exclusion criteria: Lack of consent to participate in the study Patients with kidney disease that cannot be prescribed famotidine

Design outcomes

Primary

MeasureTime frame
Mucosal lesions. Timepoint: weekly. Method of measurement: Using the Visual Analogue Scale questionnaire.;Lymphocytopenia. Timepoint: weekly. Method of measurement: Blood cell count test.;Granulocytopenia. Timepoint: weekly. Method of measurement: Blood cell count test.;Thrombocytopenia. Timepoint: weekly. Method of measurement: Blood cell count test.;Anemia. Timepoint: weekly. Method of measurement: Blood cell count test.—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactIman Fallah

Kermanshah University of Medical Sciences

Imen691020@gmail.com+98 11 3456 9701

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026